Belleudi and colleagues investigated whether switching from epoetin alpha (ESA α) to any other epoetin, compared to not switching, affected the risk of a blood transfusion or developing anemia in chronic kidney disease patients.31 This evidence concerns the gene EPO and chronic kidney disease.